The predominant expression of CCR4 in Th2 cells, as well as the upregulation of CCL17 and CCL22 in allergic diseases, have captured attention for their potential therapeutic targeting of CCR4 in the treatment of allergies [5]. Here, CCL22 is linked to allergic disease.